Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 5 Next >
News headline image
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
News headline image
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.